Description
Rtsunate (Artesunate) 100 mg
Rtsunate (Artesunate) 100 mg is presented here as an oral artesunate tablet product. Artesunate is a semisynthetic artemisinin derivative used in malaria treatment, with rapid antimalarial activity against blood-stage parasites. Publicly available official sources support artesunate as an antimalarial active ingredient, but a product-specific regulatory record for the exact trade name “Rtsunate” was not verified in the reviewed sources.
Active Ingredient and Medicine Class
The verified active ingredient is artesunate, an artemisinin-class antimalarial. It is a prodrug that is rapidly converted to dihydroartemisinin, the main active metabolite. Artesunate belongs to the endoperoxide antimalarial group and is known for its fast onset of action.
Established Medical Uses
Artesunate is used for the treatment of malaria, especially Plasmodium falciparum infection. Official and review sources distinguish between artesunate used alone for severe malaria in some settings and artesunate used in combination regimens for uncomplicated malaria. WHO prequalification records and published reviews support its role as an antimalarial medicine, while modern malaria guidance emphasizes artemisinin-based combination therapy to help reduce treatment failure and resistance.
How It Works
Artesunate acts quickly because its endoperoxide bridge is activated inside the parasite, leading to toxic reactive intermediates that damage parasite proteins and other vital structures. This effect rapidly reduces malaria parasites in the blood. Its active metabolite, dihydroartemisinin, contributes to the overall antimalarial effect after oral administration.
Important Safety Information
Artesunate should be used with attention to malaria severity, local treatment guidance, and the possibility of drug resistance. Regulatory information for artesunate products identifies serious hypersensitivity as a contraindication and recognises delayed hemolysis as an important safety concern, particularly after artesunate exposure. Human studies and reviews also note that oral artesunate has a short half-life and substantial variability in exposure, which is one reason malaria treatment commonly relies on combination therapy rather than artesunate alone.
Possible Side Effects
Reported adverse effects with artesunate include nausea, abdominal discomfort, vomiting, dizziness, rash, and laboratory abnormalities such as anemia, thrombocytopenia, and elevated liver tests. More serious reactions can include hypersensitivity and hemolytic anemia. Safety information from official artesunate labeling also recognises post-treatment hemolysis as an important serious risk.
Scientific Evidence
Clinical literature supports artesunate as a rapidly acting antimalarial, and oral pharmacokinetic studies show fast absorption followed by conversion to dihydroartemisinin. A systematic review of human pharmacokinetic studies found that oral artesunate achieves variable exposure, with concern that reduced parasite susceptibility could contribute to treatment failure in some settings. Older clinical reviews also support its established antimalarial effect and its role within combination regimens to improve cure rates and reduce recrudescence.
Medical Information Notice
This summary is for educational use only and is based on sources available at the time of review. It does not replace the official patient leaflet, local prescribing guidance, or individual assessment by a qualified healthcare professional.
Medical Sources
- World Health Organization. WHO Prequalification: Artesunate API entries and malaria-related product records. View official WHO source
- FDA. Artesunate for Injection, prescribing information. View official prescribing information
- FDA. Artesunate for Injection, medical review and product information. View official FDA review
- Public Health/WHO prequalification resources. WHO malaria product and assessment materials for artesunate-containing medicines. View WHO prequalified medicines list
- Barradell LB et al. Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria. Drugs, 1995. View scientific article
- Smith PJ et al. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malaria Journal, 2011. View scientific article
